Research in the Gale laboratory is focused on 1) understanding the basis of non-self discrimination and immune response triggering by emerging RNA viruses, 2) Defining the virus and host interactions that trigger and control innate antiviral immune defenses, 3) Identifying therapeutic targets for induction and enhancement of innate immunity against RNA virus infection, 4) Discovery and development of small molecule therapeutics as vaccine adjuvants and for the treatment of viral infection, and 5) Development of vaccines for protection against emerging RNA viruses.

The lab works very closely Kineta, a Seattle Biopharmaceutical company to translate and develop therapeutics against RNA viruses.

Find more information on the Gale Lab.Photo of Gale Lab Staff

 

Diseases we study